🧬

Multiples Top 100 BioTech Index

Curated by Multiples, this index tracks the 100 largest publicly listed biotech companies globally.

Explore the Multiples Top 100 BioTech Index

100

public companies tracked

$10.7T

cumulative enterprise value

5.3x

median EV/NTM revenue multiple

7%

median NTM/LTM revenue growth

Index Performance

This chart shows the weighted market cap evolution over time for the Multiples Top 100 BioTech Index constituents, indexed to 0% at the beginning of the period.

+51.7%

Multiples Top 100 BioTech Index

Data as of 19 November 2026. Underlying financial data from FactSet and Morningstar. S&P 500 and NASDAQ data sourced from Yahoo Finance.

Key Index Metrics

This chart shows the median evolution over time of key valuation metrics for the Multiples Top 100 BioTech Index constituents.

Valuation Benchmarks

This chart shows the regression relationship between valuation metrics across companies in the Multiples Top 100 BioTech Index.

x-axis:
y-axis:

Data as of November 19, 2026. Companies with EV multiples above 50x and y-axis values above 250% are considered non-meaningful and excluded from calculation.

Company Rankings

This chart shows company rankings by selected metric within the Multiples Top 100 BioTech Index.

Metric:

Data as of November 19, 2026. Companies with EV multiples above 50x and y-axis values above 300% are considered non-meaningful and excluded from calculation.

Companies Side-by-Side

Compare key metrics between companies in the Multiples Top 100 BioTech Index.

1:
2:
3:
Metric
Eli Lilly
Samsung
Johnson & Johnson
Market Cap
$1.2T
$929B
$656B
EV/Revenue (NTM)
12.1x
1.1x
6.4x
EV/Gross Profit (NTM)
14.4x
1.4x
8.9x
EV/EBITDA (NTM)
22.5x
1.6x
17.5x
EV/FCF (NTM)
37.9x
2.6x
26.6x
Revenue Growth
19%
46%
6%
Gross Margin (NTM)
84%
76%
72%
EBITDA Margin (NTM)
54%
65%
37%
FCF Margin (NTM)
32%
41%
24%
Rule of 40
88%
177%
44%
Rule of X
148%
353%
55%

Data as of November 19, 2026.

Cumulative Metrics

This chart shows the cumulative sum of selected metrics across all companies in the Multiples Top 100 BioTech Index, over time.

Index Methodology

Similar to the NASDAQ 100 Index, the Multiples Top 100 BioTech Index employs a modified market capitalization weighting scheme.

The weight process uses company-level weights, which are derived using company market capitalization.

Company weights are evaluated based on two rules:

Rule 1

No company's weight may exceed 24%.

Rule 2

The aggregate weight of the companies whose weights exceed 4.5% may not exceed 48%.

If neither rule is 'violated', then no adjustments are made. Only in cases where either or both of the rules are 'violated', weight adjustments are made according to a two-stage adjustment process.

Rule 1 adjustment

If no company's initial weight exceeds 24% of the Index, initial weights are used as Rule 1 weights without adjustment. Otherwise, initial weights are adjusted such that no company's weight may exceed 20% of the Index.

Rule 2 adjustment

If the aggregate weight of the companies whose Rule 1 weights exceeds 4.5% and does not exceed 48%, Rule 1 weights are used as the final weights. Otherwise, Rule 1 weights are adjusted such that:

  • The aggregate weight of the companies whose Rule 1 weights exceeded 4.5% is set to 40%.
  • Companies with Rule 1 weights below 4.5% may also have their weights adjusted to keep the initial rank order of all companies.

If the two-stage rule process results in a 'violation' of the weighting rules as previously detailed, then the process is repeated until the company weights meet the rule system.

Companies Included in the Multiples Top 100 BioTech Index

This index tracks the top 100 biotech companies across biopharmaceuticals, diagnostics, genomics, life sciences, and more.

US
12.3%
$1,383
+29%
$1.2T
12.1x
19%
84%
54%
32%
88%
$1M
KR
9.3%
$146
+113%
$929B
1.1x
46%
76%
65%
41%
177%
$2M
US
6.6%
$273
+32%
$656B
6.4x
6%
72%
37%
24%
44%
$682K
US
5.1%
$286
+26%
$506B
7.9x
9%
83%
50%
36%
59%
$1M
CH
3.8%
$480
+26%
$383B
5.2x
4%
75%
41%
24%
40%
$669K
US
3.4%
$138
+31%
$340B
5.5x
3%
82%
43%
32%
27%
$867K
CH
3.0%
$156
+21%
$295B
5.5x
7%
80%
42%
28%
42%
$753K
GB
2.8%
$182
-2%
$282B
4.7x
7%
82%
37%
19%
43%
$623K
US
2.6%
$693
+17%
$257B
5.8x
6%
43%
26%
17%
34%
$356K
US
2.4%
$444
+28%
$240B
6.8x
5%
81%
45%
28%
53%
$1M
DE
2.3%
$297
+12%
$227B
2.6x
8%
40%
18%
11%
23%
$288K
US
2.1%
$169
+34%
$210B
6.9x
7%
87%
47%
38%
14%
$2M
US
1.8%
$104
-19%
$181B
3.9x
8%
58%
27%
18%
39%
$385K
DK
1.8%
$40
-19%
$176B
4.1x
1%
81%
48%
22%
49%
$660K
US
1.6%
$229
+1%
$161B
6.5x
8%
60%
32%
23%
39%
$409K
US
1.6%
$28
+9%
$160B
3.4x
-3%
75%
38%
27%
37%
$834K
US
1.5%
$421
-27%
$146B
10.8x
13%
68%
46%
35%
65%
$591K
US
1.4%
$536
+24%
$136B
9.4x
11%
86%
42%
35%
53%
$2M
US
1.3%
$101
-4%
$129B
3.7x
5%
65%
28%
17%
33%
$383K
US
1.2%
$60
+21%
$122B
3.1x
-2%
70%
39%
29%
40%
$1M
US
1.2%
$318
-14%
$121B
4.7x
7%
65%
29%
17%
35%
$449K
FR
1.1%
$95
+91%
$114B
2.2x
6%
74%
31%
16%
38%
$686K
GB
1.0%
$25
+4%
$99B
2.7x
4%
76%
35%
15%
37%
$628K
US
1.0%
$946
+21%
$98B
4.6x
9%
94%
41%
36%
75%
$931K
US
0.8%
$197
+657%
$80B
30.1x
15%
62%
-72%
-62%
-108%
$409K
JP
0.7%
$45
-16%
$74B
7.3x
9%
73%
54%
34%
63%
$1M
DE
0.7%
$166
+23%
$72B
3.2x
6%
60%
29%
11%
31%
$373K
JP
0.7%
$43
+50%
$69B
3.2x
3%
69%
27%
17%
27%
$601K
CN
0.7%
$22
+68%
$67B
5.4x
25%
54%
51%
29%
88%
$202K
JP
0.7%
$38
+0%
$67B
2.8x
4%
54%
33%
16%
44%
$373K
AU
0.6%
$134
+10%
$64B
4.7x
1%
54%
32%
16%
9%
$523K
US
0.6%
$44
-57%
$63B
3.6x
0%
69%
31%
17%
36%
$340K
DE
0.6%
$62
+75%
$61B
1.9x
2%
57%
22%
6%
22%
$540K
US
0.6%
$105
+21%
$61B
7.6x
10%
78%
32%
22%
44%
$379K
BE
0.6%
$314
+13%
$60B
5.7x
10%
78%
40%
28%
58%
$841K
NL
0.6%
$945
+4%
$59B
7.0x
28%
90%
34%
25%
83%
$2M
CH
0.6%
$793
+16%
$55B
6.4x
10%
40%
34%
8%
42%
$386K
US
0.5%
$698
-7%
$55B
10.9x
9%
63%
36%
25%
46%
$391K
DE
0.5%
$48
-4%
$53B
1.8x
4%
37%
19%
8%
19%
$352K
CH
0.5%
$223
+12%
$52B
7.1x
20%
70%
28%
17%
50%
$690K
US
0.5%
$177
+15%
$50B
6.5x
6%
55%
30%
21%
37%
$384K
IL
0.5%
$43
+64%
$50B
3.6x
3%
55%
32%
20%
23%
$525K
KR
0.5%
$1,024
-6%
$50B
10.4x
18%
53%
51%
22%
74%
$648K
IN
0.5%
$20
-2%
$48B
6.0x
12%
80%
29%
18%
43%
$323K
US
0.5%
$31
+19%
$47B
5.4x
16%
89%
23%
15%
51%
$445K
CN
0.5%
$7
-20%
$46B
7.1x
13%
87%
31%
24%
36%
$230K
US
0.5%
$466
+16%
$46B
7.2x
16%
56%
33%
23%
137%
$401K
US
0.4%
$258
+12%
$42B
3.1x
6%
33%
23%
13%
30%
$175K
US
0.4%
$290
+21%
$42B
11.4x
23%
65%
1%
6%
24%
$376K
CH
0.4%
$97
+38%
$42B
3.7x
6%
51%
24%
8%
30%
$485K
JP
0.4%
$77
+35%
$40B
2.2x
3%
71%
22%
10%
35%
$383K
GB
0.4%
$5
-8%
$40B
3.2x
3%
67%
27%
15%
29%
$593K
US
0.4%
$84
+5%
$38B
2.0x
5%
41%
18%
9%
24%
$382K
US
0.4%
$251
+38%
$37B
4.1x
2%
79%
31%
23%
31%
$1M
KR
0.4%
$156
+29%
$36B
7.2x
20%
63%
40%
23%
77%
$1M
CH
0.4%
$74
-6%
$36B
3.4x
6%
62%
27%
15%
30%
$401K
US
0.3%
$86
-33%
$35B
4.6x
0%
70%
42%
27%
40%
$653K
US
0.3%
$160
+106%
$35B
16.4x
274%
91%
-38%
-31%
-
-
US
0.3%
$1,737
+18%
$35B
8.2x
5%
60%
32%
23%
38%
$222K
US
0.3%
$243
-14%
$34B
5.6x
4%
63%
39%
27%
40%
$497K
CN
0.3%
$28
-4%
$34B
5.4x
11%
60%
33%
29%
39%
$231K
DE
0.3%
$59
+8%
$33B
1.6x
4%
27%
17%
7%
20%
$141K
US
0.3%
$210
+60%
$32B
6.7x
7%
69%
30%
23%
35%
$431K
JP
0.3%
$17
-29%
$32B
2.0x
4%
79%
19%
11%
30%
$674K
DK
0.3%
$514
+62%
$32B
6.6x
21%
92%
33%
23%
50%
$1M
IN
0.3%
$118
+63%
$31B
18.7x
24%
67%
40%
11%
69%
$123K
CA
0.3%
$244
-29%
$31B
0.7x
90%
11%
10%
-1%
75%
$419K
US
0.3%
$83
+30%
$31B
5.3x
11%
64%
33%
22%
44%
$420K
JP
0.3%
$17
+36%
$31B
2.2x
-1%
79%
33%
23%
43%
$952K
US
0.3%
$69
+72%
$31B
10.7x
9%
-
95%
93%
144%
$24M
US
0.3%
$371
+38%
$30B
2.4x
6%
29%
18%
7%
24%
$197K
NL
0.3%
$30
+6%
$29B
1.7x
3%
48%
18%
8%
19%
$293K
US
0.3%
$260
+37%
$29B
2.7x
5%
33%
20%
13%
29%
$197K
US
0.3%
$39
+86%
$28B
63.0x
338%
87%
-247%
-158%
494%
$11K
JP
0.3%
$23
+6%
$27B
1.4x
5%
40%
16%
3%
21%
$255K
US
0.3%
$120
-42%
$26B
9.0x
67%
84%
4%
11%
190%
$364K
CN
0.3%
$4
-19%
$25B
7.3x
11%
91%
41%
42%
54%
$251K
US
0.3%
$260
-3%
$25B
4.0x
7%
45%
29%
-
34%
$331K
US
0.2%
$577
+19%
$25B
6.3x
10%
88%
47%
34%
37%
$2M
US
0.2%
$118
+13%
$24B
3.2x
5%
93%
33%
26%
34%
$2M
DE
0.2%
$247
+3%
$24B
7.0x
10%
48%
32%
15%
36%
$318K
CN
0.2%
$6
+42%
$23B
5.0x
20%
47%
39%
13%
56%
$247K
US
0.2%
$20
+90%
$23B
2.3x
4%
47%
31%
17%
34%
$477K
DE
0.2%
$82
-20%
$21B
2.1x
-6%
79%
-77%
-78%
-104%
$404K
CH
0.2%
$346
+39%
$21B
4.2x
5%
75%
28%
18%
27%
$239K
CH
0.2%
$128
+13%
$20B
5.7x
9%
72%
32%
17%
38%
$258K
US
0.2%
$149
-67%
$20B
2.8x
20%
77%
18%
18%
70%
$1M
DE
0.2%
$249
-15%
$20B
5.6x
9%
48%
31%
14%
35%
$277K
US
0.2%
$145
+34%
$20B
11.4x
35%
65%
-1%
-7%
25%
$392K
US
0.2%
$103
+6%
$20B
3.0x
3%
72%
32%
15%
37%
$484K
IN
0.2%
$49
+19%
$19B
8.7x
22%
76%
35%
23%
76%
$85K
CN
0.2%
$11
-12%
$19B
4.6x
28%
86%
19%
15%
60%
$261K
US
0.2%
$647
+9%
$18B
5.9x
7%
30%
23%
21%
35%
$383K
DK
0.2%
$270
+27%
$18B
8.0x
49%
89%
42%
38%
127%
$666K
QA
0.2%
$3
-15%
$17B
3.9x
43%
-
33%
9%
-26%
$4M
CN
0.2%
$3
-13%
$17B
3.2x
8%
69%
62%
46%
138%
$380K
US
0.2%
$152
+46%
$17B
6.4x
5%
62%
32%
22%
32%
$260K
JP
0.2%
$20
+16%
$17B
3.6x
17%
83%
45%
18%
80%
$463K
GB
0.2%
$45
-5%
$17B
4.3x
11%
46%
26%
15%
37%
$377K
US
0.2%
$68
+55%
$17B
5.6x
12%
96%
44%
-
55%
$2M

Explore More Indexes

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial